This IHP 310 Module 3 paper, complete, explains asthma pathophysiology, beta-2 receptor pharmacology, how timolol eye drops caused bronchospasm, the evidence on eye-drop beta-blockers in asthma, a mechanism-agent-monitoring table and recommendations. Searches like "ihp 310 module 3 assignment", "ihp310 module 3 respiratory drug treatment analysis" and "ihp 310 module 3 example" land here.
The IHP 310 Module 3 example, in full
A Drop in the Eye, a Squeeze in the Chest: Asthma Worsened by Timolol Eye Drops in a 62-Year-Old Woman
[Student Name]
Southern New Hampshire University
IHP 310: Pathophysiology and Pharmacology Concepts
Module Three Respiratory Assignment
[Instructor Name]
[Date]
The organization, setting and figures below are a composite written as a model document. No real employer, client, colleague or patient is described.
A Drop in the Eye, a Squeeze in the Chest: Asthma Worsened by Timolol Eye Drops in a 62-Year-Old Woman
The Case
Ms. Rahimi is a composite 62-year-old librarian with asthma since childhood. For three years it has been well controlled on a daily inhaled corticosteroid, with albuterol needed about once a month. Five weeks ago an ophthalmologist diagnosed open-angle glaucoma and started timolol 0.5 percent eye drops twice daily. Over the past month she has needed albuterol every day, wakes at night coughing twice a week, and her peak flow has fallen from about 420 to 330 liters per minute. She did not mention the eye drops to her primary care clinician because she did not think of them as medication, and her asthma history was not on the ophthalmology intake form.
The Pathophysiology of Asthma
Asthma is a chronic inflammatory disease of the airways. In response to triggers such as allergens, infections or irritants, immune cells in the airway wall release mediators that cause swelling of the lining, mucus production and contraction of airway smooth muscle. The result is airway narrowing that varies over time and is at least partly reversible. Over years, inflammation makes the airways hyperresponsive, meaning they narrow more easily and more strongly than normal airways. Controller medicines, especially inhaled corticosteroids, reduce the inflammation, and relievers open the airways during symptoms (Global Initiative for Asthma [GINA], 2024).
Beta-2 Receptors: The Link Between Airway and Eye Drop
Airway smooth muscle carries beta-2 adrenergic receptors. When stimulated, they raise cyclic AMP inside the muscle cell and relax it, widening the airway. Albuterol, a short-acting beta-2 agonist, works this way. In hyperresponsive asthmatic airways, the body's own adrenaline acting on these receptors helps hold the airways open.
Timolol is a nonselective beta-blocker. In the eye it lowers pressure by reducing the production of aqueous humor, which is why it is used for glaucoma. But drops drain through the tear ducts into the nose, where the drug is absorbed into the bloodstream and bypasses the liver's first-pass metabolism. From there it can reach the airways and block beta-2 receptors, removing the relaxing effect of adrenaline and blunting the response to albuterol. For Ms. Rahimi, the eye drop is not a local treatment but a systemic beta-blocker delivered by an unexpected route.
Considering Other Explanations
Before blaming the eye drops, a careful analysis considers the usual causes of worsening asthma. A viral respiratory infection is the most common trigger, but she has had no fever, sore throat or change in sputum. Seasonal allergens could play a part, yet her symptoms in previous autumns were mild. Poor inhaler technique or missed controller doses often explain loss of control; she demonstrates correct technique, and her pharmacy refill record shows she has collected her inhaled corticosteroid on schedule. Reflux, new pets, smoke exposure at work and new medicines such as aspirin or other anti-inflammatory drugs can also worsen asthma, and none are present. With these explanations reasonably excluded, the close timing between starting timolol and losing control, together with a known mechanism, makes the eye drops the most likely cause. The response to stopping them will confirm or refute that judgment, which is why follow-up is part of the plan.
What the Evidence Shows
This is not a theoretical risk. A population study and meta-analysis found that acute exposure to nonselective beta-blocker eye drops in people with asthma caused an average fall in forced expiratory volume in one second of about 11 percent, with one in three participants having a fall of 20 percent or more, and was associated with a significantly higher rate of moderate asthma exacerbations. Selective beta-blocker drops produced a smaller fall in lung function. Despite this, nonselective drops were still prescribed to a substantial share of people with asthma and ocular hypertension (Morales et al., 2016). Glaucoma practice guidelines list asthma and chronic obstructive pulmonary disease among the reasons to avoid or use caution with topical beta-blockers and describe several alternative drug classes (Gedde et al., 2021).
Mechanism, Agent and Monitoring
The table below summarizes the drugs involved.
Table 1
Mechanism, Agent and Monitoring for Ms. Rahimi
| Agent | Mechanism | Role in this case | Monitoring |
|---|---|---|---|
| Timolol eye drops | Nonselective beta-blocker; lowers aqueous humor production | Likely cause of worsening asthma | Stop; recheck eye pressure on new agent |
| Prostaglandin analog eye drops (for example, latanoprost) | Increase outflow of aqueous humor | Safer first-line glaucoma alternative | Eye pressure; eye redness and iris color change |
| Inhaled corticosteroid | Reduces airway inflammation | Controller; continue | Symptom control, technique, oral thrush |
| Albuterol | Short-acting beta-2 agonist; relaxes airway muscle | Reliever; overuse signals poor control | Frequency of use; response blunted by beta-blockade |
Recommendations
The primary care clinician should contact the ophthalmologist the same day to stop timolol and switch to a glaucoma drug without beta-blocking activity, most often a prostaglandin analog, with a follow-up eye pressure check in several weeks. Her asthma should be reassessed within one to two weeks, including peak flow, symptom frequency and albuterol use. If control does not return to baseline once timolol is stopped, her controller therapy should be stepped up according to asthma guidelines rather than relying on more albuterol (GINA, 2024). She should be taught to report all eye drops, creams and patches as medications.
A System Lesson
This case reflects a gap in how medication lists are built. Eye drops, prescribed by a specialist in a separate record, often do not appear on the primary care list, and patients rarely think of them as medicines. A practice can reduce this risk by asking specifically about eye drops, inhalers, patches and supplements at every medication review, and a health system can add a drug interaction alert that fires when a nonselective beta-blocker, in any form, is prescribed to a patient with an asthma diagnosis.
Conclusion
Ms. Rahimi's asthma worsened because a nonselective beta-blocker in her glaucoma drops was absorbed into her bloodstream and blocked the beta-2 receptors that keep her airways open. Understanding both the pathophysiology of asthma and the pharmacology of beta receptors explains the timeline, the blunted response to albuterol and the solution: a glaucoma drug that works by a different mechanism, with monitoring of both her eyes and her lungs.
References
Gedde, S. J., Vinod, K., Wright, M. M., Muir, K. W., Lind, J. T., Chen, P. P., Li, T., & Mansberger, S. L. (2021). Primary open-angle glaucoma preferred practice pattern. Ophthalmology, 128(1), P71-P150. https://doi.org/10.1016/j.ophtha.2020.10.022
Global Initiative for Asthma. (2024). Global strategy for asthma management and prevention. https://ginasthma.org
Morales, D. R., Dreischulte, T., Lipworth, B. J., Donnan, P. T., Jackson, C., & Guthrie, B. (2016). Respiratory effect of beta-blocker eye drops in asthma: Population-based study and meta-analysis of clinical trials. British Journal of Clinical Pharmacology, 82(3), 814-822. https://doi.org/10.1111/bcp.13006
How this IHP 310 Module 3 example is structured
The assignment asks for mechanism, agent and monitoring together, so the paper keeps them linked. It opens with the case and the timeline that raises suspicion. Asthma's pathophysiology comes next, followed by the receptor pharmacology that connects the airway to the eye drop. The research on eye-drop beta-blockers in asthma is then reported. A table sets out each relevant drug with its mechanism and the monitoring it requires, and the paper ends with recommendations and a system lesson about medication lists.
Get IHP 310 Module 3 written to your instructions
Send your IHP 310 Module 3 prompt, rubric and case details. A respiratory analysis that pairs mechanism, agent and monitoring to your case comes back within 24 to 48 hours; the first is free. The paper above is an original model document written by our desk, not a submitted student paper and not an official Southern New Hampshire University document.
IHP 310 Module 3 questions, answered
What does IHP 310 Module 3 usually cover?
Many pathophysiology and pharmacology courses cover the respiratory system at this point, including asthma and chronic obstructive pulmonary disease, and the drug classes used for them, such as bronchodilators and inhaled corticosteroids. An assignment may ask for the mechanism of disease, the agent and how treatment is monitored.
How can eye drops affect the lungs?
Drops drain through the tear ducts into the nose, where they are absorbed into the bloodstream without first passing through the liver. A beta-blocker absorbed this way can reach the airways and block the beta-2 receptors that keep airway muscles relaxed, which can trigger bronchospasm in people with asthma.
What is the difference between selective and nonselective beta-blockers?
Selective beta-blockers act mainly on beta-1 receptors in the heart, while nonselective ones, such as timolol and propranolol, also block beta-2 receptors in the airways. Nonselective agents carry greater risk for people with asthma, although selective agents are not entirely free of respiratory effects.